USANA Health Sciences (NYSE:USNA) Director Gilbert Fuller Sells 1,057 Shares

USANA Health Sciences, Inc. (NYSE:USNAGet Free Report) Director Gilbert Fuller sold 1,057 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $18.66, for a total value of $19,723.62. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

USANA Health Sciences Trading Down 1.9%

Shares of USANA Health Sciences stock opened at $18.38 on Wednesday. The company’s 50-day moving average price is $18.24 and its two-hundred day moving average price is $19.48. USANA Health Sciences, Inc. has a 52 week low of $16.60 and a 52 week high of $38.32. The stock has a market cap of $339.35 million, a PE ratio of 39.11, a price-to-earnings-growth ratio of 0.74 and a beta of 0.77.

USANA Health Sciences (NYSE:USNAGet Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The firm had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, equities analysts predict that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on USNA shares. Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Zacks Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

Read Our Latest Report on USANA Health Sciences

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Pzena Investment Management LLC raised its holdings in USANA Health Sciences by 1.2% during the 3rd quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock worth $33,407,000 after buying an additional 14,328 shares during the period. Renaissance Technologies LLC raised its holdings in USANA Health Sciences by 1.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock worth $22,522,000 after buying an additional 21,793 shares during the period. Vanguard Group Inc. raised its holdings in USANA Health Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after buying an additional 57,249 shares during the period. Dimensional Fund Advisors LP raised its holdings in USANA Health Sciences by 1.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after buying an additional 17,318 shares during the period. Finally, Nantahala Capital Management LLC acquired a new stake in USANA Health Sciences during the 4th quarter worth about $11,485,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

(Get Free Report)

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

Featured Stories

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.